Luoxin Pharmaceuticals Hits Day Low at CNY 4.20 Amid Price Pressure

Luoxin Pharmaceuticals Group Stock Co., Ltd. experienced a significant decline today, with shares dropping by 8.6% to reach an intraday low of CNY 4.20. This performance starkly contrasts with the broader market, as the China Shanghai Composite index fell by 3.63% during the same period. Over the past week, Luoxin's stock has decreased by 12.19%, and its monthly performance shows a decline of 12.55%. Year-to-date, the stock has lost 11.46%, while its performance over the last three years has plummeted by 42.72%. In the five-year span, the stock has seen a substantial decrease of 58.41%. Financial metrics indicate challenges for Luoxin Pharmaceuticals, including a low Return on Capital Employed (ROCE) of 3.79% and a Return on Equity (ROE) of -33.60%. The company has also faced declining net sales, which have contracted at an annual rate of 25.90%. With a market capitalization of CNY 5,278 million, Luoxin operates within the pharmaceuticals and biotechnology sector, where it continues to navigate a complex financial landscape.